Skip to main
PAVM

PAVmed (PAVM) Stock Forecast & Price Target

PAVmed (PAVM) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PAVmed Inc. has demonstrated a steady increase in test processing for its EsoGuard product, with 2,841 tests completed in Q3, showcasing growth compared to previous quarters. The company's valuation reflects a balance between the inherent risks of early-stage commercialization and the substantial upside potential associated with its innovative products. Additionally, the anticipated significant growth in revenue from its various lines of business, particularly in the upcoming years, supports a strong outlook for the company.

Bears say

PAVmed Inc reported a pro forma net loss of $0.8 million, indicating a deterioration compared to prior estimates and highlighting ongoing financial challenges within the company. The decline in EsoGuard test volumes—from 3,034 in Q1 to 2,756 in Q2—reflects decreasing demand and potential operational hurdles that could impede future revenue growth. Additionally, the company's reliance on early-stage products like Lucid and Veris, coupled with substantial risks related to product approval, commercialization, and market competition, further contributes to a negative outlook for PAVmed's stock.

PAVmed (PAVM) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PAVmed (PAVM) Forecast

Analysts have given PAVmed (PAVM) a Strong Buy based on their latest research and market trends.

According to 1 analysts, PAVmed (PAVM) has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PAVmed (PAVM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.